全球數位生物標記市場規模、佔有率、成長分析，依類型、臨床實踐、治療領域（心血管和代謝疾病、呼吸系統疾病）、最終用途 - 2024-2031 年產業預測

2022年全球數位生物標記市場規模約29.6億美元，預計將從2023年的36.1億美元增至2031年的175.9億美元，預測期（2024-2031年）複合年成長率為21.9% ） 。

由於與健康相關的行動應用程式和互聯數位裝置的快速採用，以及智慧型手機使用的日益普及、新型穿戴裝置的推出以及治療領域應用的拓寬，該市場有望擴大。期待已久的批准使患者及其醫療保健提供者能夠更深入地了解心臟健康，包括早期發現表明心血管疾病的特定心律不整。因此，數位生物標記市場正在經歷大幅成長。此外，在旨在加快數位生物標記研究的金融和投資活動加強的推動下，預計醫療保健產業將在預測期內出現成長。此外，眾多健康科技公司貢獻了其數位生物標記技術來對抗 COVID-19 大流行，進一步推動市場擴張。 Medopad 與國際合作夥伴之間的合作旨在加快驗證過程，識別呼吸指標等關鍵資料點的數位生物標記，並找出感染 COVID-19 風險較高的個人，從而使市場受益。此外，數位生物標記的範圍超出了智慧手錶和活動追蹤器。大型製藥公司正在與創新的數位健康新創公司合作，加速該技術的採用，並增強數位生物標記領域的新穎解決方案，從而促進市場成長。政府組織認知到 COVID-19 大流行帶來的嚴峻課題，並表示有興趣開發基於數位生物標記的藥物。儘管數位生物標記物提供了無數優勢，但某些障礙，例如對資料隱私、可靠性、資料驗證和缺乏開源資料的擔憂，預計將阻礙市場成長。然而，在預測期內，日益激烈的競爭和這些系統的擴大利用預計將克服這些課題。

目錄

執行摘要

• 市場概況
• 命運之輪

研究方法論

• 資訊採購
• 二手和主要資料來源
• 市場規模估計
• 市場假設與限制

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題

主要市場洞察

• 技術分析
• 定價分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• 啟動分析
• 原料分析
• 創新矩陣
• 管道產品分析
• 總體經濟指標
• 頂級投資分析
• 成功的關鍵因素
• 競爭程度

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題
• 監管環境
• 波特分析
• 對未來顛覆的特別見解

依類型分類的全球數位生物標記市場

• 市場概況
• 穿戴式
• 基於行動的應用程式
• 感應器
• 其他

依臨床實踐分類的全球數位生物標記市場

• 市場概況
• 診斷數位生物標記
• 監測數位生物標記
• 預測和預後數位生物標記物
• 其他（安全
• 藥效學/反應
• 敏感性）

依治療領域分類的全球數位生物標記市場

• 市場概況
• 心血管和代謝疾病（CVMD）
• 呼吸系統疾病
• 精神疾病
• 睡眠與運動疾病
• 神經系統疾病
• 肌肉骨骼疾病
• 和其他（糖尿病
• 疼痛管理）

依最終用途分類的全球數位生物標記市場

• 市場概況
• 醫療保健公司
• 醫療保健機構
• 付款人
• 和其他（患者
• 照顧者）

全球數位生物標記市場規模（依地區）

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • MEA 的其餘部分

競爭格局

• 前 5 名企業比較
• 2021 年關鍵參與者的市場定位
• 主要市場參與者所採取的策略
• 最佳制勝策略
• 近期市集活動
• 主要公司市佔率（%），2021年

主要公司簡介

• ActiGraph LLC
• AliveCor Inc.
• Koneksa
• Altoida Inc.
• Amgen Inc.
• Biogen Inc.
• Empatica Inc.
• Vivo Sense
• IXICO plc
• Adherium Limited
• Neurotrack Technologies, Inc.
• Aural Analytic
• Huma
• Sonde Health, Inc.
• Clario
• Imagene AI
• Brainomix
• Kinsa Inc.
• Feel Therapeutics
• ResApp (Pfizer)

Global digital biomarkers market size was valued at around USD 2.96 billion in 2022 and is expected to rise from USD 3.61 billion in 2023 to reach a value of USD 17.59 billion by 2031, at a CAGR of 21.9 % over the forecast period (2024-2031).

The market is poised for expansion owing to the rapid adoption of health-related mobile applications and connected digital devices, alongside the increasing prevalence of smartphone usage, the introduction of novel wearables, and the broadening applications in therapeutic domains. The much-awaited approval is empowering patients and their healthcare providers with deeper insights into cardiac health, including the early detection of specific arrhythmias indicative of cardiovascular disease. Consequently, the market for digital biomarkers is experiencing a substantial growth surge. Moreover, the healthcare sector is expected to witness growth over the forecast period, fueled by heightened financial and investment activities aimed at expediting research on digital biomarkers. Additionally, numerous health technology companies have contributed their digital biomarker technologies to combat the COVID-19 pandemic, further driving market expansion. Collaborations, such as that between Medopad and international partners, aim to expedite the validation process, identify digital biomarkers for critical data points like respiratory indicators, and pinpoint individuals at higher risk for COVID-19, thus benefitting the market. Furthermore, the scope of digital biomarkers extends beyond smartwatches and activity trackers. Major pharmaceutical companies are teaming up with innovative digital health start-ups to accelerate the adoption of this technology and enhance novel solutions in the realm of digital biomarkers, thereby fostering market growth. Government organizations, acknowledging the profound challenges posed by the COVID-19 pandemic, are expressing interest in developing medications based on digital biomarkers. Despite the myriad advantages offered by digital biomarkers, certain obstacles, such as concerns regarding data privacy, reliability, data validation, and the absence of open-source data, are anticipated to impede market growth. However, during the forecast period, increasing competition and expanded utilization of these systems are expected to surmount these challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the global digital biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Digital Biomarkers Market Segmental Analysis

The global digital biomarkers market is segmented based on type, clinical practice, therapeutic area, end-use, and region. By type, the market is segmented into wearable, mobile based applications, sensors, and others. By clinical practice, the market is segmented into diagnostic digital biomarkers, monitoring digital biomarkers, predictive, and prognostic digital biomarkers, and others (safety, pharma co-dynamics/ response, susceptibility). By therapeutic areas, the market is segmented into cardiovascular and metabolic disorders (CVMD), respiratory disorders, psychiatric disorders, sleep & movement disease, neurological disorders, musculoskeletal disorders, and others (diabetes, pain management). By end-use, the market is segmented into healthcare companies, healthcare providers, payers, others (patient, caregivers). By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Digital Biomarkers Market

The increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is fueling the demand for digital biomarkers. These biomarkers play a crucial role in the early detection and management of these conditions.

Restraints in the Global Digital Biomarkers Market

The absence of definitive regulatory guidelines for digital biomarkers is impeding the growth of this market by creating uncertainty for investors and manufacturers alike.

Market Trends of the Global Digital Biomarkers Market

The growing popularity of wearables and mobile health apps among both consumers and healthcare providers is fueling the expansion of the digital biomarkers market. These technologies facilitate continuous and remote monitoring of patients, generating substantial amounts of data that can be leveraged to develop digital biomarkers.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Digital Biomarkers Market by Type

• Market Overview
• Wearable
• Mobile based Applications
• Sensors
• and Others

Global Digital Biomarkers Market by Clinical Practice

• Market Overview
• Diagnostic digital biomarkers
• Monitoring digital biomarkers
• Predictive and Prognostic digital biomarkers
• Other's (Safety
• Pharmacodynamics/ Response
• Susceptibility)

Global Digital Biomarkers Market by Therapeutic Area

• Market Overview
• Cardiovascular and metabolic disorders (CVMD)
• Respiratory disorders
• Psychiatric disorders
• Sleep & Movement Disease
• Neurological disorders
• Musculoskeletal disorders
• and Others (Diabetes
• Pain Management)

Global Digital Biomarkers Market by End-Use

• Market Overview
• Healthcare companies
• Healthcare Providers
• Payers
• and Others (Patient
• caregivers)

Global Digital Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• ActiGraph LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AliveCor Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koneksa
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altoida Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Empatica Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivo Sense
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IXICO plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adherium Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotrack Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aural Analytic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonde Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clario
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imagene AI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Brainomix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kinsa Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Feel Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ResApp (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments